-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 40th JP Morgan Healthcare Conference will be held online from January 10-13, 2022
10x Genomics is targeting clinical and translational markets with a new RNA analysis kit for paraformaldehyde-fixed samples
Antibody and T cell receptor discovery platforms, dubbed BEAM-ab and BEAM-T, respectively, will also be launched in 2022
In an in-house experiment, researchers at 10x Genomics sought to discover antibodies to the new coronavirus, SARS-CoV-2
For the Visium spatial transcriptomics platform, Saxonov reiterated that the 10x CytAssist instrument will be available this year
Saxonov also debuted the company's in situ analysis platform, called Xenium, which will work on both fixed and fresh-frozen samples to provide single-molecule DNA, RNA and protein detection at subcellular resolution
10x has been promising an in-situ analytics platform since acquiring ReadCoor and Cartana in 2020
10x Genomics will offer a "technical trial" of Xenium later this year, with the goal of an official launch in 2023
Justin McAnear, 10x's chief financial officer, said in a question-and-answer session that the company noticed a decrease in user activity in its European labs since December, which it attributed to the spread of the SARS-CoV-2 Omicron variant
Saxonov noted that there are currently 3,500 instruments installed in laboratories around the world